Barclays Maintains an 'Overweight' on Teva Pharma (TEVA); Detailed Laquinimod Results Support Our Positive View
Tweet Send to a Friend
Barclays maintains an 'Overweight' on Teva Pharma (NASDAQ: TEVA), PT $70.
Barclays analyst says, "First-time detailed laquinimod Phase 3 results ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Barclays analyst says, "First-time detailed laquinimod Phase 3 results ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
